MX2021006463A - Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. - Google Patents
Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.Info
- Publication number
- MX2021006463A MX2021006463A MX2021006463A MX2021006463A MX2021006463A MX 2021006463 A MX2021006463 A MX 2021006463A MX 2021006463 A MX2021006463 A MX 2021006463A MX 2021006463 A MX2021006463 A MX 2021006463A MX 2021006463 A MX2021006463 A MX 2021006463A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- msh3
- activity
- treatment
- disorders associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862774791P | 2018-12-03 | 2018-12-03 | |
| US201962877142P | 2019-07-22 | 2019-07-22 | |
| PCT/US2019/064054 WO2020117702A1 (en) | 2018-12-03 | 2019-12-02 | Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006463A true MX2021006463A (es) | 2021-09-28 |
Family
ID=70974779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006463A MX2021006463A (es) | 2018-12-03 | 2019-12-02 | Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220072028A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7714162B6 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102970906B1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2019394847A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3121779A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX2021006463A (cg-RX-API-DMAC10.html) |
| WO (2) | WO2020117702A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021216556A2 (en) * | 2020-04-20 | 2021-10-28 | University Of Massachusetts | Oligonucleotides for msh3 modulation |
| EP4146807A4 (en) * | 2020-05-08 | 2024-09-04 | Takeda Pharmaceuticals U.S.A., Inc. | METHODS OF TREATING NUCLEOTIDE AMPLIFICATION DISEASES ASSOCIATED WITH MSH3 ACTIVITY |
| US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| EP4247392A4 (en) * | 2020-06-03 | 2025-10-08 | Takeda Pharmaceuticals Usa Inc | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY |
| EP4164656A4 (en) * | 2020-06-11 | 2025-10-22 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION |
| WO2022256631A2 (en) * | 2021-06-04 | 2022-12-08 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| WO2023168304A2 (en) * | 2022-03-02 | 2023-09-07 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
| WO2024251211A1 (en) * | 2023-06-06 | 2024-12-12 | Revir Therapeutics, Inc. | Compositions, methods, and systems for modulating splicing of msh3 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999010369A1 (en) * | 1997-08-28 | 1999-03-04 | Thomas Jefferson University | Compositions, kits, and methods for effecting adenine nucleotide modulation of dna mismatch recognition proteins |
| US20050244851A1 (en) * | 2004-01-13 | 2005-11-03 | Affymetrix, Inc. | Methods of analysis of alternative splicing in human |
| WO2008157747A1 (en) | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
| US20140303235A1 (en) * | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
| WO2015171918A2 (en) * | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| EP3806850A2 (en) * | 2018-06-15 | 2021-04-21 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| US11408000B2 (en) * | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| WO2022256631A2 (en) * | 2021-06-04 | 2022-12-08 | Triplet Therapeutics, Inc. | Methods for the treatment of nucleotide repeat expansion disorders associated with msh3 activity |
-
2019
- 2019-12-02 WO PCT/US2019/064054 patent/WO2020117702A1/en not_active Ceased
- 2019-12-02 MX MX2021006463A patent/MX2021006463A/es unknown
- 2019-12-02 JP JP2021553755A patent/JP7714162B6/ja active Active
- 2019-12-02 AU AU2019394847A patent/AU2019394847A1/en active Pending
- 2019-12-02 CA CA3121779A patent/CA3121779A1/en active Pending
- 2019-12-02 KR KR1020217020797A patent/KR102970906B1/ko active Active
- 2019-12-02 WO PCT/US2019/064055 patent/WO2020117703A1/en not_active Ceased
- 2019-12-02 US US17/299,186 patent/US20220072028A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7714162B6 (ja) | 2025-09-08 |
| JP2022510041A (ja) | 2022-01-25 |
| WO2020117702A1 (en) | 2020-06-11 |
| US20220072028A1 (en) | 2022-03-10 |
| AU2019394847A1 (en) | 2021-07-22 |
| KR102970906B1 (ko) | 2026-05-29 |
| KR20210099090A (ko) | 2021-08-11 |
| CA3121779A1 (en) | 2020-06-11 |
| WO2020117703A1 (en) | 2020-06-11 |
| JP7714162B2 (ja) | 2025-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12021550698A1 (en) | Compositions and methods for treating or preventing diseases and/or disorders caused by exposure to air pollution | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| PH12022550165A1 (en) | Interleukin-2 agents and uses thereof | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MY205689A (en) | Antibody molecules to cd138 and uses thereof | |
| MX379543B (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| SA520412283B1 (ar) | Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ | |
| MX388693B (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| ZA202208280B (en) | Antibody molecules to c5ar1 and uses thereof | |
| MX2020008106A (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos. | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| CL2021000744A1 (es) | Métodos para tratar trastornos mieloproliferativos | |
| EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| PH12021553109A1 (en) | Humanized antibody molecules to cd138 and uses thereof | |
| MX2020000611A (es) | Composiciones y metodos para tratar trastornos relacionados con el estres. | |
| EA201991395A1 (ru) | Новые композиции для лечения суставных нарушений | |
| EA202092824A1 (ru) | Комбинированная терапия | |
| MX2023009895A (es) | Compuestos y composiciones para tratar la fibrosis. |